News
Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...
The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback